Proniras secures funding for Phase I opiate withdrawal study
PRIVATEFeb 02, 2024
Amount Raised
$4.65 Million
Round Type
Seed
SeattleBiotechnology
Description
Proniras has announced the successful completion of a $4.65m Series B funding round for a trial of a new treatment for opiate withdrawal. This investment will support the Phase I clinical study of PRN-001-01 (tezampanel), a new therapy for opiate withdrawal.
Who to call at Proniras, and when
A new round usually means Proniras is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Proniras raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Proniras, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Proniras. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Proniras
Location
2815 EASTLAKE AVENUE EAST, SUITE 300
Seattle, Washington, United States
About
Proniras Corporation is a clinical-stage biotechnology developing novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system disorders. The Company’s lead program PRN-001-01 (tezampanel) is being clinical developed as a treatment option for opioid withdrawal and related disorders of addiction. Although effective treatments exist for opioid addiction, painful and difficult withdrawal is one of the primary reasons why current treatment fails, and relapse occurs. By alleviating the symptoms associated with opioid withdrawal, Proniras hopes to help patients successfully discontinue opioid usage and sustain an opioid-free life. Proniras was formed in 2017 by Accelerator Life Science Partners.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Proniras raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
SeattleBiotechnology